These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Angiogenesis as a strategic target for ovarian cancer therapy. Spannuth WA; Sood AK; Coleman RL Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in the treatment of ovarian cancer. Han ES; Monk BJ Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559 [TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Teoh D; Secord AA Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Liotta M; Rose PG; Escobar PF Gynecol Oncol; 2009 Nov; 115(2):308-9. PubMed ID: 19740533 [No Abstract] [Full Text] [Related]
7. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Han ES; Monk BJ Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545 [No Abstract] [Full Text] [Related]
8. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer. Al Wadi K; Ghatage P Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765 [TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy and surgical practice. John AR; Bramhall SR; Eggo MC Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790 [TBL] [Abstract][Full Text] [Related]
10. Development of antiangiogenic therapies for ovarian cancer. Markowska A; Lubin J; Madry R; Markowska J Eur J Gynaecol Oncol; 2013; 34(4):303-6. PubMed ID: 24020134 [TBL] [Abstract][Full Text] [Related]
11. New ways to successfully target tumor vasculature in ovarian cancer. Yang X; Shen F; Hu W; Coleman RL; Sood AK Curr Opin Obstet Gynecol; 2015 Feb; 27(1):58-65. PubMed ID: 25502429 [TBL] [Abstract][Full Text] [Related]
12. Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Sánchez-Muñoz A; Pérez-Ruiz E; Mendiola Fernández C; Alba Conejo E; González-Martín A Clin Transl Oncol; 2009 Sep; 11(9):589-95. PubMed ID: 19775998 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease: angiogenesis and the management of breast cancer. Banerjee S; Dowsett M; Ashworth A; Martin LA Nat Clin Pract Oncol; 2007 Sep; 4(9):536-50. PubMed ID: 17728712 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286 [TBL] [Abstract][Full Text] [Related]
16. Drug insight: VEGF as a therapeutic target for breast cancer. Schneider BP; Sledge GW Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858 [TBL] [Abstract][Full Text] [Related]
17. Breast tumour angiogenesis. Fox SB; Generali DG; Harris AL Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723 [TBL] [Abstract][Full Text] [Related]
18. New therapeutic agents in ovarian cancer. Collinson F; Jayson G Curr Opin Obstet Gynecol; 2009 Feb; 21(1):44-53. PubMed ID: 19125003 [TBL] [Abstract][Full Text] [Related]